DCNet
DCNet infers cellular composition from bulk RNA-Seq data using an explainable deep neural network to characterize tumor microenvironment (TME) heterogeneity.
Key Features:
- Deep Learning-Based Framework: DCNet employs an explainable artificial neural network architecture incorporating visible design principles for model interpretability.
- Integration of Cell-Marker Relationships: The model embeds relationships between cell types and their marker genes within the neural network framework.
- High-Resolution Cellular Inference: DCNet infers a cellular landscape comprising over 400 distinct cell types from bulk RNA-Seq data.
- Robustness and Stability: The model accurately recapitulates cell landscapes in multiple single-cell RNA-Seq datasets, demonstrating robustness and stability.
- Clinical Relevance: Applied to TCGA patient data, DCNet stratifies patients into groups with significant differences in survival times and distinct cellular compositions.
Scientific Applications:
- Tumor Microenvironment Characterization: Provides detailed cellular composition of TMEs to study how cellular heterogeneity influences tumor behavior.
- Immunotherapy Research: Identifies patient subgroups with distinct immune profiles that may predict responses to immunotherapy.
- Clinical Stratification and Survival Analysis: Enables stratification of TCGA cohorts by cellular composition to investigate associations with patient survival.
Methodology:
DCNet trains an explainable deep neural network on bulk RNA-Seq data while explicitly modeling cell type–marker gene relationships and validates inferred compositions against single-cell RNA-Seq datasets.
Topics
Details
- License:
- Not licensed
- Tool Type:
- library
- Operating Systems:
- Mac, Linux, Windows
- Programming Languages:
- Python
- Added:
- 6/24/2022
- Last Updated:
- 11/24/2024
Operations
Publications
Wang X, Wang H, Liu D, Wang N, He D, Wu Z, Zhu X, Wen X, Li X, Li J, Wang Z. Deep learning using bulk RNA-seq data expands cell landscape identification in tumor microenvironment. OncoImmunology. 2022;11(1). doi:10.1080/2162402x.2022.2043662. PMID:35251771. PMCID:PMC8890395.
PMID: 35251771
PMCID: PMC8890395
Funding: - Natural Science Foundation of: 621MS041, 821MS0777, No.821MS045
- National Natural Science Foundation of: No.31701159
- Major Science and Technology Program of Hainan Province: No.ZDKJ202003